Life Sciences

  • August 10, 2026

    Lack Of Fiduciary Duty Frees Chemours From NC PFAS Suit

    Chemours Inc., its affiliates and DuPont Industrial Biosciences USA LLC on Monday got the dismissal of a proposed class action by a North Carolina resident over contamination of Brunswick County's water.

  • August 10, 2026

    Alto Neuroscience Escapes Investor Drug Trial Suit, For Now

    Alto Neuroscience has escaped a shareholder suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, with a California federal judge ruling that the suit's "vague and conclusory" pleadings should be remedied.

  • August 10, 2026

    Fed. Circ. Reverses PTAB On Prior Art Issue Over Dental IP

    The Federal Circuit on Monday reversed a Patent Trial and Appeal Board decision that invalidated a group of claims in a Dental Monitoring SAS dental imaging patent, finding that a previous provisional patent application was missing a written description and thus can't be used as prior art.

  • August 10, 2026

    Judge Blocks DOD Military Label For Chinese Biotech Co.

    A D.C. federal judge temporarily blocked the U.S. Department of Defense from enforcing a decision to designate WuXi AppTec Co. Ltd. as a Chinese military company, ruling the department's justifications appeared to lack a grounding in the evidence they cited.

  • August 10, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving merger settlements, contract claims, controlling stockholders, music rights, prejudgment interest, absentee voting and stockholder standing.

  • August 10, 2026

    Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push

    Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. 

  • August 10, 2026

    EU Sets Antidumping Duties On Plastic Compound Imports

    A chemical compound used in plastic production has been found to have been sold at less than fair value in the European Union, and imports from South Korea and Mexico will face antidumping duties, the European Commission announced Monday.

  • August 07, 2026

    3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India

    The Third Circuit has ruled that a dispute between Merck and a defunct Indian pharmaceutical company over a terminated relationship belongs in India.

  • August 07, 2026

    VA To Test Psilocybin For Veterans With Severe Depression

    Former military service members in five U.S. cities will have an opportunity to treat their depression with psilocybin through a clinical trial being run by the U.S. Department of Veterans Affairs, according to an agency announcement.

  • August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

  • August 07, 2026

    J&J Fax Sent To Pharmacy An Unwanted Ad, 3rd Circ. Says

    In a precedential opinion Friday, the Third Circuit ruled a two-page fax Johnson & Johnson sent to a Florida pharmacy about its drug Xarelto was an unsolicited advertisement, reversing a lower court's finding and reviving a class claim filed by the pharmacy alleging the drugmaker violated the Telephone Consumer Protection Act.

  • August 07, 2026

    New Squires Order Institutes 4 Patent Reviews, Denies 6

    U.S. Patent and Trademark Office Director John Squires has instituted review of four patents and denied six other petitions in his latest round of decisions.

  • August 07, 2026

    KKR Buying Medicover's India Business In $1.4B Deal

    Global investment firm KKR has agreed to acquire Medicover Hospitals India, Swedish healthcare provider Medicover AB's Indian hospital operations business, in a transaction that values the platform at about €1.2 billion ($1.4 billion).

  • August 07, 2026

    Nat'l Science Org. To Review Judiciary's Nixed Climate Chapter

    The National Academy of Sciences will review the process used to develop a controversial chapter on climate science that has been removed from the federal judiciary's guide to scientific evidence, according to a Friday announcement.

  • August 07, 2026

    Eli Lilly Launches Attacks On Tirzepatide Generics

    Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sandoz, MSN Laboratories and others.

  • August 07, 2026

    Cooley Leads 2 Biotech Firms Pricing IPOs Totaling $496M

    Two biotechnology firms began trading publicly Friday after raising a combined $496 million in their initial public offerings, with Cooley LLP advising both companies and Latham & Watkins LLP advising both underwriters.

  • August 07, 2026

    Taxation With Representation: Slaughter And May, Covington

    In this week's Taxation With Representation, U.K. real estate investment trust Segro's board agrees to a share offer from U.S. rival Prologis with a partial cash alternative, Curium acquires fellow radiopharmaceutical company Lantheus Holdings Inc., and investment firm KKR buys medical device company Integer Holdings Corp.

  • August 06, 2026

    Mead Preemption Bid Fails Before 1st Baby Formula MDL Trial

    An Illinois federal judge on Wednesday said Mead Johnson & Co. must face the first bellwether trial next week in multidistrict litigation over baby formula that allegedly was defective and harmed premature babies, rejecting the company's argument that the recent U.S. Supreme Court Monsanto decision blocks the plaintiff's claims.

  • August 06, 2026

    USPTO Leaders Reinstate Double Patenting Ax In Sanofi Case

    A panel including U.S. Patent and Trademark Office Director John Squires ruled Thursday that a Sanofi patent application must be rejected for double patenting, but questioned whether the rationale for the decision risks harming innovation and should be reconsidered by the Federal Circuit.

  • August 06, 2026

    Mark Zuckerberg's Foundation Can Arbitrate Gender Bias Suit

    A California federal judge on Thursday sent to arbitration claims that the foundation run by Meta CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women, saying the suit's sexual harassment claims weren't sufficiently severe or pervasive to invalidate the plaintiff's arbitration agreement.

  • August 06, 2026

    SEC Nets Win In Suit Over Ex-CEO's Alleged Revenue Scheme

    A Washington, D.C., federal judge on Thursday largely sided with the U.S. Securities and Exchange Commission in its civil enforcement case against the former CEO of RTI Surgical Holdings, finding he misled investors by failing to disclose that the surgical implant company regularly shipped orders early to artificially inflate its quarterly revenues.

  • August 06, 2026

    SpineFrontier CFO Sentenced To 4 Months In Kickback Case

    The former chief financial officer of spinal implant startup SpineFrontier was sentenced Thursday to four months in prison for his involvement in an alleged conspiracy to pay surgeons kickbacks disguised as consulting fees.

  • August 06, 2026

    GOP Sens. Vote To Hold Fauci In Contempt, AGs Open Probe

    A U.S. Senate committee voted along party lines Thursday to hold Dr. Anthony Fauci in contempt of Congress after he declined to answer questions about the government's handling of the pandemic, while the Florida, West Virginia and Louisiana attorneys general are investigating potential "self-dealing" by Fauci during the crisis.

  • August 06, 2026

    Judge Sets Feb. Trial In States' Generics Price-Fixing Suit

    A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.

  • August 06, 2026

    Goodwin, Covington Lead Braveheart Bio's $383M IPO

    Venture-backed biotechnology firm Braveheart Bio hit the public markets on Thursday after raising $383 million in its upsized initial public offering.

Expert Analysis

  • Series

    Bass Fishing Makes Me A Better Lawyer

    Author Photo

    Landing a trophy striped bass and closing a big deal both require cultivating the patience to finesse — not force — your way to desired outcomes, changing course when your old approach isn’t working and learning from the ones that got away, says Jon Ruiss at Alston & Bird.

  • How Reincorporating In Texas May Alter Earnout Disputes

    Author Photo

    While the DExit debate has focused on shareholder suits, far less attention has been paid to what reincorporating in Texas means for M&A disputes, making it particularly important to understand the nuances between Delaware and Texas earnout jurisprudence, say attorneys at Selendy Gay.

  • Roundup

    The Most Talked-About Supreme Court Decisions Of 2026

    Author Photo

    This term, 11 U.S. Supreme Court decisions quickly became hot topics among Law360's guest writers.

  • Coordinating Life Sciences IP Strategies In The US And EU

    Author Photo

    As postgrant practice for life sciences patents is restructured in the U.S. and European Union simultaneously, patent owners will need to implement transatlantic coordination that treats international proceedings as components of a single intellectual property risk architecture, says Paul Calvo at Sterne Kessler.

  • What Durnell Ruling Means For Mo. Roundup Settlement

    Author Photo

    While the U.S. Supreme Court’s recent ruling in Monsanto v. Durnell forecloses the failure-to-warn theory that carried most of the claims against Monsanto in a pending class action in Missouri state court, it leaves untouched the question of whether the class was assembled merely to contain the defendant's liability, says attorney Gregg Goldfarb.

  • Why Biotech Cos. Need Litigation Plans Before Bad News

    Author Photo

    Biotech companies should take proactive steps to respond to the growing trend of securities litigation filed against them, due to the inherently uncertain nature of their business models and heightened scrutiny of clinical trial disclosures, regulatory communications and investor-facing statements, says Wesley Horton at FBFK.

  • 10 Years, 150 Cases: The Rise And Fall Of Post-Halo Damages

    Author Photo

    When the U.S. Supreme Court decided Halo v. Pulse in 2016, patent practitioners predicted that enhanced damages would become easier to win, but analysis of every contested district court ruling on a motion for enhanced damages in the last 10 years shows that courts have shown increasing restraint, say attorneys at Reichman Jorgensen.

  • Legal Risks Of Using AI To Screen Psychedelic Trial Patients

    Author Photo

    Though using artificial intelligence to preemptively identify drug trial participants likely to experience placebo effects could produce clearer research results, sponsors will need to be ready for the new legal questions these methods raise about informed consent, accountability for algorithmically derived criteria, and potential bias in data training sets, says Kimberly Chew at Husch Blackwell.

  • After Durnell, Connecting Science And Causation Will Be Key

    Author Photo

    The U.S. Supreme Court's June 25 decision in Monsanto v. Durnell narrowed label-based failure-to-warn claims — meaning that going forward, viable theories will depend even more on whether experts can reliably connect scientific evidence to the causal proposition the law requires, says Alex Smolak at Weill Cornell Medicine-Qatar.

  • Series

    Choral Singing Makes Me A Better Lawyer

    Author Photo

    Singing in the New York City Bar Chorus — a hobby partly inspired by the late U.S. District Judge Richard Owen, who infused my clerkship year with opera music — has improved my legal career by refining my abilities to listen, exude confidence and develop emotional intelligence, says Bonnie Baker at Friedman Kaplan.

  • Attorney Mental Health Is An Ethical Obligation In The AI Era

    Author Photo

    As attorneys cope with the increasing unpredictability that artificial intelligence and constant policy changes have created, particularly in practice areas where they carry the emotional weight of clients’ most consequential life events, otherwise soft discussions about self-care are a matter of professional competence, says attorney Jack Jrada.

  • The Case For Using Final-Offer Damages Forms In IP Suits

    Author Photo

    Recent Federal Circuit decisions, such as Ollnova v. Ecobee, that scrutinize verdict forms in patent infringement disputes potentially render the final-offer damages selection procedure more attractive, though it should not be seen as a replacement for patent damages doctrine, says Brandon Theiss at Addy Hart.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • $885M IBS Drug Verdict Tests Pay-For-Delay Limits

    Author Photo

    The outcome in the Amitiza Antitrust Litigation is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment since the U.S. Supreme Court adopted the rule-of-reason legal framework in 2013, offering a blueprint for pay-for-delay claims, say attorneys at Katten.

  • Series

    Power To The Paralegals: Burnout As A Structural Problem

    Author Photo

    Law firm leadership can best retain their paralegals not by encouraging self-care, but by seeking top-down structural solutions for the quiet proliferation of responsibilities and the vicarious exposure to client trauma that particularly drive burnout in this vital role, says Erika Sneeringer at Brockstedt Mandalas.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.